Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1230

1.

Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress.

Mayer K, Mundigl O, Kettenberger H, Birzele F, Stahl S, Pastan I, Brinkmann U.

Redox Biol. 2018 Sep 26;20:146-156. doi: 10.1016/j.redox.2018.09.015. [Epub ahead of print]

2.

Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.

Shancer Z, Williams M, Igelman A, Nagata S, Ise T, Pastan I, Bera TK.

Antib Ther. 2018 Jun;1(1):19-25. doi: 10.1093/abt/tby004. Epub 2018 Aug 20.

3.

Interplay Between Reversible Phosphorylation and Irreversible Adp-Ribosylation of Eukaryotic Translation Elongation Factor 2.

Mateus-Seidl R, Stahl S, Dengl S, Birzele F, Herrmuth H, Mayer K, Niederfellner G, Liu XF, Pastan I, Brinkmann U.

Biol Chem. 2018 Sep 1. pii: /j/bchm.just-accepted/hsz-2018-0280/hsz-2018-0280.xml. doi: 10.1515/hsz-2018-0280. [Epub ahead of print]

PMID:
30218597
4.

Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.

Mazor R, King E, Pastan I.

Cell Immunol. 2018 Aug 28. pii: S0008-8749(18)30377-0. doi: 10.1016/j.cellimm.2018.08.016. [Epub ahead of print]

PMID:
30213644
5.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

6.

Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.

Müller F, Cunningham T, Beers R, Bera TK, Wayne AS, Pastan I.

Toxins (Basel). 2018 May 21;10(5). pii: E210. doi: 10.3390/toxins10050210.

7.

Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.

Mazor R, King EM, Pastan I.

Am J Pathol. 2018 Aug;188(8):1736-1743. doi: 10.1016/j.ajpath.2018.04.016. Epub 2018 Jun 2. Review.

PMID:
29870741
8.

Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering.

Kaplan G, Mazor R, Lee F, Jang Y, Leshem Y, Pastan I.

Mol Cancer Ther. 2018 Jul;17(7):1486-1493. doi: 10.1158/1535-7163.MCT-17-1041. Epub 2018 Apr 25.

PMID:
29695631
9.

Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.

Wei J, Bera TK, Liu XF, Zhou Q, Onda M, Ho M, Tai CH, Pastan I.

Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3501-E3508. doi: 10.1073/pnas.1721780115. Epub 2018 Mar 26.

10.

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I.

Blood. 2018 May 24;131(21):2331-2334. doi: 10.1182/blood-2017-09-803072. Epub 2018 Feb 27.

PMID:
29487070
11.

5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.

Müller F, Cunningham T, Stookey S, Tai CH, Burkett S, Jailwala P, Stetler Stevenson M, Cam MC, Wayne AS, Pastan I.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1867-E1875. doi: 10.1073/pnas.1714512115. Epub 2018 Feb 5.

12.

Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.

King EM, Mazor R, Çuburu N, Pastan I.

J Immunol. 2018 Mar 15;200(6):2038-2045. doi: 10.4049/jimmunol.1701430. Epub 2018 Feb 5.

PMID:
29431691
13.

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.

Mazor R, King EM, Onda M, Cuburu N, Addissie S, Crown D, Liu XF, Kishimoto TK, Pastan I.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E733-E742. doi: 10.1073/pnas.1717063115. Epub 2018 Jan 8. Review.

14.

Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway.

Liu XF, Zhou Q, Hassan R, Pastan I.

Oncotarget. 2017 Aug 14;8(50):87307-87316. doi: 10.18632/oncotarget.20263. eCollection 2017 Oct 20.

15.

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients.

Bera TK, Abe Y, Ise T, Oberle A, Gallardo D, Liu XF, Nagata S, Binder M, Pastan I.

Leukemia. 2018 Feb;32(2):569-572. doi: 10.1038/leu.2017.315. Epub 2017 Nov 17. No abstract available.

16.

Cancer vaccine strategies: translation from mice to human clinical trials.

Berzofsky JA, Terabe M, Trepel JB, Pastan I, Stroncek DF, Morris JC, Wood LV.

Cancer Immunol Immunother. 2017 Nov 15. doi: 10.1007/s00262-017-2084-x. [Epub ahead of print] Review.

PMID:
29143114
17.

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock JA, Stetler-Stevenson M, Sun W, Liang M, Yang J, Kreitman RJ, Lanasa MC, Pastan I.

Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.

18.

Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury.

Lim BJ, Yang JW, Zou J, Zhong J, Matsusaka T, Pastan I, Zhang MZ, Harris RC, Yang HC, Fogo AB.

Kidney Int. 2017 Dec;92(6):1395-1403. doi: 10.1016/j.kint.2017.04.010. Epub 2017 Jul 12.

PMID:
28709637
19.

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.

Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I.

Cancer Immunol Res. 2017 Aug;5(8):685-694. doi: 10.1158/2326-6066.CIR-16-0330. Epub 2017 Jul 3.

20.

Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.

Inaguma S, Wang Z, Lasota J, Onda M, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Pastan I, Miettinen M.

Oncotarget. 2017 Apr 18;8(16):26744-26754. doi: 10.18632/oncotarget.15814.

21.

Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.

Müller F, Stookey S, Cunningham T, Pastan I.

Oncotarget. 2017 May 9;8(19):30644-30655. doi: 10.18632/oncotarget.16141.

22.

Specific CpG hyper-methylation leads to Ankrd26 gene down-regulation in white adipose tissue of a mouse model of diet-induced obesity.

Raciti GA, Spinelli R, Desiderio A, Longo M, Parrillo L, Nigro C, D'Esposito V, Mirra P, Fiory F, Pilone V, Forestieri P, Formisano P, Pastan I, Miele C, Beguinot F.

Sci Rep. 2017 Mar 7;7:43526. doi: 10.1038/srep43526.

23.

5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia.

Marconi C, Canobbio I, Bozzi V, Pippucci T, Simonetti G, Melazzini F, Angori S, Martinelli G, Saglio G, Torti M, Pastan I, Seri M, Pecci A.

J Hematol Oncol. 2017 Jan 18;10(1):18. doi: 10.1186/s13045-016-0382-y.

24.

Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.

Mazor R, Kaplan G, Park D, Jang Y, Lee F, Kreitman R, Pastan I.

Cell Immunol. 2017 Mar;313:59-66. doi: 10.1016/j.cellimm.2017.01.003. Epub 2017 Jan 5.

25.

Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.

Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.

Appl Microbiol Biotechnol. 2017 Apr;101(7):2747-2766. doi: 10.1007/s00253-016-8063-x. Epub 2016 Dec 24.

26.

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I.

J Clin Oncol. 2016 Dec;34(34):4171-4179. Epub 2016 Oct 31. Review.

27.

Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin.

Mazor R, Addissie S, Jang Y, Tai CH, Rose J, Hakim F, Pastan I.

AAPS J. 2017 Jan;19(1):117-129. doi: 10.1208/s12248-016-9986-y. Epub 2016 Oct 27.

PMID:
27796910
28.

Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.

Thomas A, Chen Y, Berman A, Schrump DS, Giaccone G, Pastan I, Venzon DJ, Liewehr DJ, Steinberg SM, Miettinen M, Hassan R, Rajan A.

Lung Cancer. 2016 Nov;101:104-110. doi: 10.1016/j.lungcan.2016.09.015. Epub 2016 Sep 28.

PMID:
27794397
29.

Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.

Zhang J, Khanna S, Jiang Q, Alewine C, Miettinen M, Pastan I, Hassan R.

Clin Cancer Res. 2017 Mar 15;23(6):1564-1574. doi: 10.1158/1078-0432.CCR-16-1667. Epub 2016 Sep 15.

30.

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.

Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, Madan RA, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA.

Oncoimmunology. 2016 Jul 1;5(8):e1197459. doi: 10.1080/2162402X.2016.1197459. eCollection 2016 Aug.

31.

Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis.

Liu XF, Xiang L, Zhou Q, Carralot JP, Prunotto M, Niederfellner G, Pastan I.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10666-71. doi: 10.1073/pnas.1611481113. Epub 2016 Sep 6.

32.

3D Culture Supports Long-Term Expansion of Mouse and Human Nephrogenic Progenitors.

Li Z, Araoka T, Wu J, Liao HK, Li M, Lazo M, Zhou B, Sui Y, Wu MZ, Tamura I, Xia Y, Beyret E, Matsusaka T, Pastan I, Rodriguez Esteban C, Guillen I, Guillen P, Campistol JM, Izpisua Belmonte JC.

Cell Stem Cell. 2016 Oct 6;19(4):516-529. doi: 10.1016/j.stem.2016.07.016. Epub 2016 Aug 25.

33.

Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.

Antignani A, Mathews Griner L, Guha R, Simon N, Pasetto M, Keller J, Huang M, Angelus E, Pastan I, Ferrer M, FitzGerald DJ, Thomas CJ.

PLoS One. 2016 Aug 24;11(8):e0161415. doi: 10.1371/journal.pone.0161415. eCollection 2016.

34.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

35.

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.

Kaplan G, Lee F, Onda M, Kolyvas E, Bhardwaj G, Baker D, Pastan I.

Toxins (Basel). 2016 Jul 25;8(8). pii: E217. doi: 10.3390/toxins8080217.

36.

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.

Wang C, Gao W, Feng M, Pastan I, Ho M.

Oncotarget. 2017 May 16;8(20):32450-32460. doi: 10.18632/oncotarget.10592.

37.

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.

Awuah P, Bera TK, Folivi M, Chertov O, Pastan I.

Mol Cancer Ther. 2016 Jul;15(7):1648-55. doi: 10.1158/1535-7163.MCT-15-0863. Epub 2016 May 18.

38.

Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria.

Liang X, Schnaper HW, Matsusaka T, Pastan I, Ledbetter S, Hayashida T.

PLoS One. 2016 May 17;11(5):e0155534. doi: 10.1371/journal.pone.0155534. eCollection 2016.

39.

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.

Mazor R, Onda M, Park D, Addissie S, Xiang L, Zhang J, Hassan R, Pastan I.

Oncotarget. 2016 May 24;7(21):29916-26. doi: 10.18632/oncotarget.9171.

40.

Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.

Müller F, Cunningham T, Liu XF, Wayne AS, Pastan I.

Clin Cancer Res. 2016 Oct 1;22(19):4913-4922. Epub 2016 Apr 25.

41.

Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens.

Guha R, Mathews Griner LA, Keller JM, Zhang X, Fitzgerald D, Antignani A, Pastan I, Thomas CJ, Ferrer M.

J Biomol Screen. 2016 Oct;21(9):942-55. doi: 10.1177/1087057116644890. Epub 2016 Apr 25.

PMID:
27112173
42.

Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.

Liu X, Müller F, Wayne AS, Pastan I.

Mol Cancer Ther. 2016 May;15(5):1053-62. doi: 10.1158/1535-7163.MCT-15-0828. Epub 2016 Mar 3.

43.

Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy.

Illei PB, Alewine C, Zahurak M, Cowan ML, Montgomery E, Hassan R, Xiang L, Pastan I, Kelly RJ.

Appl Immunohistochem Mol Morphol. 2016 Apr;24(4):246-52. doi: 10.1097/PAI.0000000000000292.

44.

Immunogenicity of therapeutic recombinant immunotoxins.

Mazor R, Onda M, Pastan I.

Immunol Rev. 2016 Mar;270(1):152-64. doi: 10.1111/imr.12390. Review.

45.

Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.

Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD.

Invest New Drugs. 2016 Apr;34(2):149-58. doi: 10.1007/s10637-015-0318-3. Epub 2016 Jan 4.

46.

Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.

Ali-Rahmani F, FitzGerald DJ, Martin S, Patel P, Prunotto M, Ormanoglu P, Thomas C, Pastan I.

Cancer Res. 2016 Mar 15;76(6):1560-8. doi: 10.1158/0008-5472.CAN-15-2401. Epub 2015 Dec 30.

47.

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.

Bao X, Pastan I, Bigner DD, Chandramohan V.

Receptors Clin Investig. 2016;3(4). pii: e1430. doi: 10.14800/rci.1430.

48.

Immunoconjugates in the management of hairy cell leukemia.

Kreitman RJ, Pastan I.

Best Pract Res Clin Haematol. 2015 Dec;28(4):236-45. doi: 10.1016/j.beha.2015.09.003. Epub 2015 Oct 9. Review.

49.

Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.

Mazor R, Crown D, Addissie S, Jang Y, Kaplan G, Pastan I.

Cell Mol Immunol. 2017 May;14(5):432-442. doi: 10.1038/cmi.2015.91. Epub 2015 Oct 19.

50.

New Life for Immunotoxin Cancer Therapy.

Hassan R, Alewine C, Pastan I.

Clin Cancer Res. 2016 Mar 1;22(5):1055-8. doi: 10.1158/1078-0432.CCR-15-1623. Epub 2015 Oct 13.

Supplemental Content

Loading ...
Support Center